Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Apply for the ASN Home Dialysis Scholarship 2025-6 Program by May 31, 2025 Posted 05-20-2025
- Vantive is Supporting ASN’s Centers of Excellence in Home Dialysis Program Posted 05-20-2025
- NKF Spring Clinical Meeting Home Dialysis Posters Posted 04-23-2025
- Visit the MEI Booth (#100) at the Upcoming ANNA National Symposium Posted 04-23-2025